# IGM Biosciences, Inc.

IGM Biosciences, Inc. is a company headquartered in Mountain View, CA, United States.

## Company overview

- **Legal name:** IGM Biosciences, Inc.
- **Former names in filing history:** Palingen, Inc. (2010-07-16 to 2010-07-16)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Mountain View, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001496323

## About

IGM Biosciences, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001496323, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2025-03-06, it reported net income of USD -195,795,000; total assets of USD 265,712,000 for the fiscal period ended 2024-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2024-12-31)

- **Net income:** -$195.8M (USD -195,795,000)
- **Total assets:** $265.7M (USD 265,712,000)
- **Cash and equivalents:** $26.5M (USD 26,495,000)
- **Operating cash flow:** -$153.0M (USD -152,996,000)

### FY2023 (period ended 2023-12-31)

- **Net income:** -$246.4M (USD -246,416,000)
- **Total assets:** $423.4M (USD 423,411,000)
- **Cash and equivalents:** $112.5M (USD 112,520,000)
- **Operating cash flow:** -$192.2M (USD -192,231,000)

### FY2022 (period ended 2022-12-31)

- **Net income:** -$221.1M (USD -221,102,000)
- **Total assets:** $513.5M (USD 513,499,000)
- **Cash and equivalents:** $121.2M (USD 121,231,000)
- **Operating cash flow:** -$5.9M (USD -5,853,000)

### FY2021 (period ended 2021-12-31)

- **Net income:** -$165.2M (USD -165,164,000)
- **Total assets:** $298.1M (USD 298,127,000)
- **Cash and equivalents:** $133.3M (USD 133,334,000)
- **Operating cash flow:** -$124.3M (USD -124,339,000)
- **Later filings:** Operating cash flow: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2025-08-14 — period 2025-08-14 — 8-K
- Form 10-Q — filed 2025-07-31 — period 2025-06-30 — 10-Q
- Form 8-K — filed 2025-07-01 — period 2025-07-01 — 8-K
- Form 8-K — filed 2025-06-11 — period 2025-06-06 — 8-K
- Form 8-K — filed 2025-05-29 — period 2025-05-23 — 8-K
- Form 10-Q — filed 2025-05-13 — period 2025-03-31 — 10-Q
- Form 8-K — filed 2025-05-08 — period 2025-05-05 — 8-K
- Form 10-K/A — filed 2025-04-30 — period 2024-12-31 — 10-K/A
- Form 10-K — filed 2025-03-06 — period 2024-12-31 — 10-K
- Form 8-K — filed 2025-01-10 — period 2025-01-07 — 8-K
- Form 8-K — filed 2024-11-08 — period 2024-11-08 — 8-K
- Form 10-Q — filed 2024-11-08 — period 2024-09-30 — 10-Q

---

Updated: 2026-10-23T19:32:55Z

Canonical page: https://altss.com/profile/igm-biosciences-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology